Sivem Pharmaceuticals Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Sivem Pharmaceuticals Pharmaceutical Import Records from India — 4 Products, $5.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sivem Pharmaceuticals — Pharmaceutical Importer Profile (2026) | 4 Products, $5.0M Trade | TransData Nexus

Sivem Pharmaceuticals

Pharmaceutical Importer · United States · Antivirals Focus · $5.0M Total Trade · DGFT Verified

Sivem Pharmaceuticals is a pharmaceutical importer based in United States with a total trade value of $5.0M across 4 products in 3 therapeutic categories. Based on 188 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Sivem Pharmaceuticals sources from 3 verified Indian suppliers, with Aurobindo Pharma Limited accounting for 83.0% of imports.

Sivem Pharmaceuticals — Import Portfolio & Supplier Network

Sivem Pharmaceuticals import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Sivem Pharmaceuticals?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Aurobindo Pharma Limited	$15.5M	441	83.0%
Sun Pharmaceutical Industries Limited	$1.8M	131	9.8%
Intas Pharmaceuticals Limited

What Formulations Does Sivem Pharmaceuticals Import?

Formulation	Value	Ships
Venlafaxine 150MG capsules	$1.9M	40
Valaciclovir tablets 500MG	$1.6M	31
Mirtazapine tablets 30MG (mirtazapine	$950.0K	19
Pharma drugs & medi sivem-quetiapine	$427.4K	16
Cefalexin tablets BP 500MG (cephalexin	$231.5K	6
Finasteride tablets 5MG (finasteride 5MG	$209.6K	5
Trandolapril capsules 2MG	$182.6K	5
Venlafaxine capsules 75MG (venlafaxine	$150.0K	3
Valaciclovir tablets 500MG valacyclovirtablets 500 MG	$150.0K	3
Escitalopram 10 MG tablets escitalopram10mg	$150.0K	3
Sertraline 100MG capsules (sertraline 100MG) (58656x100's Pack	$150.0K	3
Sertraline capsules 50MG (sertraline 50MG) (87648x100's Pack	$150.0K	3
Sertraline 100MG capsules (sertraline	$145.9K	3
Venlafaxine capsules 75 MG (venlafaxinexr 75 MG) (44400x100's Pack)	$139.1K	3
Venlafaxine capsules 75MG (venlafaxine xr 75MG) (44496x100's Pack	$137.6K	3

Sivem Pharmaceuticals imports 331 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Acyclovir	Antivirals	$1.6M	31	1.2%	6
2	Valacyclovir	Antivirals	$1.6M	31	1.7%	5
3	Cephalexin	Antibiotics	$1.3M	28	0.4%	17
4	Simvastatin	Cardiovascular	$587.8K	98	0.5%	16

Sivem Pharmaceuticals imports 4 pharmaceutical products across 3 categories into United States totaling $5.0M.

Sivem Pharmaceuticals — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Sivem Pharmaceuticals is a private label brand specializing in the distribution of generic pharmaceutical products across Canada. Established in 2012 and headquartered in Saint-Laurent, Quebec, the company offers a portfolio of over 100 molecules and 366 stock-keeping units (SKUs). (sivem.ca) Their mission centers on providing reliable and quality generic drugs to support pharmacists in their daily operations.

In addition to its Canadian operations, Sivem Pharmaceuticals has engaged in importing finished pharmaceutical formulations from India into the United States. Between 2022 and 2026, the company imported a total of $5.0 million USD worth of pharmaceutical products from India, encompassing 188 shipments. These imports included four distinct products across three therapeutic categories: antivirals, antibiotics, and cardiovascular drugs. The top five imported products were Acyclovir and Valacyclovir (each accounting for $1.6 million USD), Cephalexin ($1.3 million USD), and Simvastatin ($588,000 USD). Notably, the top five products constituted 100% of the company's import portfolio during this period.

2Distribution Network

Sivem Pharmaceuticals operates a distribution network that spans both Canada and the United States. In Canada, the company maintains a centralized warehouse located at 4705 Dobrin Street, Saint-Laurent, Quebec. (sivem.ca) This facility serves as the hub for their operations, ensuring efficient supply chain management and timely delivery of products to pharmacies across the country.

In the United States, Sivem Pharmaceuticals has been importing pharmaceutical products through various ports, including Newark, New Jersey, and New York, New York. The company's import activities from India have involved ports such as Jawaharlal Nehru Port in India, Colombo in Sri Lanka, and Kajang in Malaysia. These logistics operations indicate a well-established network capable of managing international shipments and distribution within the U.S. market.

3Industry Role

Sivem Pharmaceuticals functions as a pharmaceutical importer and distributor, focusing on sourcing generic drug formulations from international markets, particularly India, and supplying them to the U.S. market. By importing finished pharmaceutical formulations, the company plays a role in enhancing the availability of generic medications, thereby contributing to the affordability and accessibility of healthcare in the United States. Their operations support the broader pharmaceutical supply chain by introducing cost-effective alternatives to brand-name drugs, which can lead to reduced healthcare expenditures for both consumers and the healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Sivem Pharmaceuticals

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Sivem Pharmaceuticals' sourcing strategy exhibits a high degree of concentration, with 100% of their imported products originating from three Indian suppliers: Aurobindo Pharma Limited, Sun Pharmaceutical Industries Limited, and Intas Pharmaceuticals Limited. This concentrated sourcing approach suggests a strategic decision to establish strong partnerships with key manufacturers, potentially ensuring consistent product quality and supply reliability.

However, such dependency on a limited number of suppliers can pose risks, including vulnerability to supply chain disruptions, regulatory changes affecting specific manufacturers, or geopolitical issues in the supplier's country. The shipment data indicates a stable relationship with these suppliers, as evidenced by the consistent number of shipments over the years. Nonetheless, the lack of diversification in sourcing could impact Sivem Pharmaceuticals' ability to adapt to market changes or mitigate risks associated with supplier-specific challenges.

2Supply Chain Resilience

Sivem Pharmaceuticals' supply chain resilience is closely tied to the stability and reliability of its Indian suppliers. The company's focus on a limited number of suppliers may streamline operations but also increases exposure to potential disruptions. The absence of backup suppliers in the available data suggests a reliance on these key partners for product availability.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA ensures that all drugs entering the U.S. meet standards for quality, safety, and effectiveness, as mandated by the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Key legislation governing pharmaceutical imports includes the FD&C Act, which outlines requirements for drug approval, labeling, and manufacturing practices. Additionally, the Drug Enforcement Administration (DEA) regulates controlled substances, and the Customs and Border Protection (CBP) agency enforces import laws. The FDA's Office of Global Policy and Strategy's India Office collaborates with Indian regulatory authorities to ensure compliance with U.S. standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. are stringent. Importers must ensure that their products comply with FDA regulations, including obtaining necessary approvals and certifications. Good Manufacturing Practice (GMP) certification is a critical component of this compliance. The FDA recognizes GMP certifications from various international standards, including EU GMP, WHO GMP, and PIC/S, provided they meet FDA criteria.

Importers must also obtain wholesale distribution authorization, which involves registering with the FDA and adhering to specific state regulations. This process ensures that imported drugs are distributed in a manner consistent with U.S. laws and regulations.

Sivem Pharmaceuticals — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Sivem Pharmaceuticals' focus on importing generic drugs in the therapeutic areas of antivirals, antibiotics, and cardiovascular medications aligns with significant market demand in the United States. The high import values of Acyclovir and Valacyclovir indicate a strong market need for antiviral treatments, particularly for conditions like herpes simplex virus infections. Similarly, the importation of Cephalexin and Simvastatin addresses ongoing requirements for antibiotics and cholesterol-lowering agents, respectively.

The company's product strategy appears to be driven by the need to provide cost-effective alternatives to brand-name drugs, thereby enhancing accessibility for patients and reducing healthcare costs. By focusing on these therapeutic areas, Sivem Pharmaceuticals positions itself to meet critical healthcare needs while capitalizing on the substantial market opportunities within the U.S. pharmaceutical sector.

2Sourcing Profile

Sivem Pharmaceuticals' sourcing strategy emphasizes the procurement of generic drug formulations from India, a country renowned for its robust pharmaceutical manufacturing capabilities. The company's preference for finished pharmaceutical formulations over active pharmaceutical ingredients (APIs) suggests a focus on ready-to-market products that can be swiftly integrated into the U.S. supply chain.

India's pharmaceutical industry is recognized for its adherence to international quality standards, including GMP certifications. This aligns with Sivem Pharmaceuticals' commitment to ensuring the quality

Frequently Asked Questions — Sivem Pharmaceuticals

What products does Sivem Pharmaceuticals import from India?

Sivem Pharmaceuticals imports 4 pharmaceutical products across 3 categories. Top imports: Acyclovir ($1.6M), Valacyclovir ($1.6M), Cephalexin ($1.3M), Simvastatin ($587.8K).

Who supplies pharmaceuticals to Sivem Pharmaceuticals from India?

Sivem Pharmaceuticals sources from 3 verified Indian suppliers. The primary supplier is Aurobindo Pharma Limited (83.0% of imports, $15.5M).

What is Sivem Pharmaceuticals's total pharmaceutical import value?

Sivem Pharmaceuticals's total pharmaceutical import value from India is $5.0M, based on 188 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Sivem Pharmaceuticals focus on?

Sivem Pharmaceuticals imports across 3 categories. The largest: Antivirals (61.7%), Antibiotics (26.6%), Cardiovascular (11.7%).

Get Full Sivem Pharmaceuticals Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.